ANRO
Alto Neuroscience, Inc.
Key Financials
EPS (Diluted)
$-2.19
↑ 12.4%
Net Income
$-63238000
↓ 2.9%
Operating Income
$-66364000
↑ 3.3%
Total Liabilities
$33.5M
↑ 28.6%
Total Assets
$184.7M
↑ 4.0%
Cash & Equivalents
$176.5M
↑ 4.9%
Shareholders' Equity
$151.1M
↓ 0.2%
Long-term Debt
$16.2M
↑ 57.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 10/1/2026 | View on SEC |
| 144 | 9/29/2026 | View on SEC |
| 8-K | 8/27/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 10-Q | 8/12/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| SCHEDULE 13G | 7/27/2026 | View on SEC |
| SCHEDULE 13G | 7/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ANRO |
| Company Name | Alto Neuroscience, Inc. |
| CIK | 1999480 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 773-255-5012 |